RankAlpha logo
Back to Rankings

AYTU

Aytu BioPharmaA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
EXXUA's first full launch quarter produced $3.9 million in revenue and sharply higher prescriptions while Aytu retained $26.3 million of cash at June 30. Durable refill and reimbursement economics could support operating leverage.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
EXXUA's early prescribing, refill, reimbursement and gross-to-net patterns may change as the launch scales.
Momentum
100
Value
53
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.15 · Bull $3.10 · Bear $1.10Analysis 2026-10-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.67
Why
Momentum100 · Δ7d -
Value53 · Δ7d -0.0
Sentiment63 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • EXXUA's early prescribing, refill, reimbursement and gross-to-net patterns may change as the launch scales.
  • • Fiscal 2026 adjusted EBITDA was negative despite a positive fiscal Q4; sustained cash earnings remain unproven.
  • • Full-year revenue declined 13.3%, adjusted EBITDA turned negative, and generic competition continues to pressure ADHD sales.

Catalyst clock

2026-12-31

EXXUA prescription-to-revenue conversion

Lead driver: Sentiment · See AI snapshot
Momentum
100
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
53
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
63
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 99.5 / Value 52.9 / Sentiment 62.7

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method

B+
Bull case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$2.15
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$20.98M
Beta
0.37
Shares Out
10.87M
P/E (TTM)
15.7
P/S (TTM)
0.46
P/FCF (TTM) · Derived
5.59
Rev YoY
-32.7%
EPS YoY
-353.1%
Gross Margin
+60.1%
Op Margin
-12.2%
Net Debt
-$8.02M
Current Ratio
1.12
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data